+39 339 659 6105 info@hepbcppa.org

Menu
Strategy meeting to eliminate viral hepatitis in Germany 2022

Strategy meeting to eliminate viral hepatitis in Germany 2022

February 9, 2022, 2:00 pm to 5:45 pm

The treatment of chronic hepatitis C with direct-acting antiviral substances (DAAs) is one of the most important clinical advances in recent medical history. This means that hepatitis C can now be treated very well in almost all patients and even cured in a short time, almost without side effects. Hepatitis B can be well controlled with the approved drugs. A new drug for the treatment of hepatitis delta has recently become available.

For some years now, the instruments for a worldwide elimination of hepatitis B and hepatitis C, as sought by the World Health Organization (WHO), have actually been available. Nevertheless, viral hepatitis is still a major global and EU-wide health problem. In order to discuss with experts from medicine and politics how the elimination of viral hepatitis in Germany can succeed, the German Liver Foundation in cooperation with the Hepatitis B & C Public Policy Association (HepBCPPA) is organizing the “Strategy Meeting to Eliminate Viral Hepatitis in Germany 2022” on February 9, 2022 (2:00 pm to 5:45 pm). The event will take place in a virtual format.

Die Behandlung der chronischen Hepatitis C mit direkt wirkenden antiviralen Substanzen (DAAs) ist einer der wichtigsten klinischen Fortschritte der jüngeren Medizingeschichte. Damit kann die Hepatitis C inzwischen bei fast allen Patienten sehr gut behandelt und in kurzer Zeit, nahezu ohne Nebenwirkungen, sogar geheilt werden. Die Hepatitis B kann mit den zugelassenen Medikamenten gut kontrolliert werden. Für die Therapie der Hepatitis delta ist seit Kurzem ein neues Medikament verfügbar.

So steht seit einigen Jahren eigentlich das Instrumentarium für eine weltweite Elimination der Hepatitis B und Hepatitis C, wie sie von der Weltgesundheitsorganisation WHO angestrebt wird, zur Verfügung. Trotzdem stellt die Virushepatitis noch immer ein großes globales und EU-weites Gesundheitsproblem dar. Um mit Experten aus Medizin und Politik zu diskutieren, wie die Elimination der Virushepatitis in Deutschland gelingen kann, organisiert die Deutsche Leberstiftung in Kooperation mit der Hepatitis B & C Public Policy Association (HepBCPPA) das „Strategietreffen Virushepatitis in Deutschland eliminieren 2022“ am 9. Februar 2022 (14:00 bis 17:45 Uhr). Die Veranstaltung wird in einem virtuellen Format stattfinden.

Programme

2:00 p.m. Viral hepatitis in Europe  – Introduction

Heiner Wedemeyer,
Hepatitis B & C Public Policy Association / Hannover Medical School

2:15 p.m. Welcome

Angelos Hatzakis
Hepatitis B & C Public Policy Association

2:20 pm Viral hepatitis 2022 in Germany – Background

Chair/Moderation:
Heiner Wedemeyer, Hepatitis B & C Public Policy Association / Hannover Medical School;
Stefan Zeuzem, German Liver Foundation / University Hospital Frankfurt

Virus hepatitis – Facts and Figures
Ruth Zimmermann,
Robert Koch Institute, Berlin

Viral hepatitis – the clinical problem
Christoph Sarrazin, Deutsche Leberhilfe / St. Josefs Hospital, Wiesbaden

Viral hepatitis – Knowledge in the population
Miriam Gerlich, Federal Centre for Health Education

Viral hepatitis – vulnerable groups
Stefan Christensen, Center for Interdisciplinary Medicine, Münster

Panel discussion
Stefan Christensen, Center for Interdisciplinary Medicine, Münster; Christoph Sarrazin, Deutsche Leberhilfe / St. Josefs Hospital, Wiesbaden; Egbert Trowe, Liver Transplanted Germany; Ruth Zimmermann, Robert Koch Institute, Berlin; NN (MEP); NN (MdB)

3:30 pm Introduction to the workshops / Break

3:45 pm Workshops

Workshop 1: Viral hepatitis in prison

Moderation : Marc Lehmann, Prison Hospital Plötzensee, Berlin;
Participants: Bärbel Knorr, Deutsche Aidshilfe; Simone Widhalm, Institute for Health Projects; NN (MdB)

Workshop 2: Viral hepatitis in vulnerable groups

Moderation: Patrick Ingiliz, Hôpitaux Universitaires Henri Mondor, Créteil, France;
Participants: Dirk Schäffer, Deutsche Aidshilfe; Heino Stöver, Frankfurt University of Applied Sciences; Christel Lüdecke, Asklepios Fachklinikum Göttingen; NN; NN (MdB)

Workshop 3: Screening for viral hepatitis in GU

Moderation: Markus Cornberg, Hannover Medical School
Participants: Peter Buggisch, ifi – Institute for Interdisciplinary Medicine, Hamburg; Anja Neumann, University of Duisburg-Essen; NN (MdB)

4:30 p.m. Reports from the three workshops

Marc Lehmann, Prison Hospital Plötzensee, Berlin; Patrick Ingiliz, Hôpitaux Universitaires Henri Mondor, Créteil, France; Markus Cornberg, Hannover Medical School / German Liver Foundation

4:45 p.m. Germany 2022 – how do we achieve the WHO goals?

Chair/Moderation: Ulrike Protzer, Helmholtz Zentrum / Technische Universität München

Panel discussion

Achim Kautz,
Deutsche Leberhilfe; NN (Federal Ministry of Health); NN (Public Health Service); NN (MEP); NN (health insurance); NN (general practitioner)

Position Paper – Presentation, Discussion and Decision-Making
Heiner Wedemeyer,
Hepatitis B & C Public Policy Association / Hannover Medical School

5:30 pm Farewell

Heiner Wedemeyer,
Hepatitis B & C Public Policy Association / Hannover Medical School


OrganizerDeutsche Leberstiftung in cooperation with the Hepatitis B & C Public Policy Association, Carl-Neuberg-Straße 1, 30625 Hannover
www.deutsche-leberstiftung.de

All contributors work voluntarily for the German Liver Foundation.

Financial Support 

This event has been supported by grants from AbbVie and Gilead Sciences Europe